drugset / Trial / NCT05776043
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
Phase 3
Unknown
1364 enrolled
Medical University of Warsaw
Autonomous Public Specialist Western John Paul II Hospital in Grodzisk Mazowiecki · collabJerzy Popiełuszko Bielański Hospital in Warsaw · collabJohn Paul II Hospital, Krakow · collabLudwik Rydygier Regional Polyclinical Hospital in Toruń · collabMedical University of Gdansk · collabMedical University of Graz · collabMedical University of Silesia in Katowice · collabMedical University of Vienna · collabNicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz · collabPoznan University of Medical Sciences · collabRegional Polyclinical Hospital in Kielce · collabUniversity Clinical Center of the Medical University of Warsaw · collabUniversity Clinical Hospital Military Medical Academy, Central Veterans Hospital in Łódź · collabUniversity Teaching Hospital in Białystok · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
National, multicenter, randomized, double-blind, parallel-group, stratified by SGLT-2 inhibitor type, placebo-controlled trial, - a Phase III study. Primary objective of the study is to investigate the impact of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on clinical endpoints in patients hospitalized with acute/decompensated HF.
Timeline
- Start
- 2022-03-15
- Primary completion
- 2024-09-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | Empagliflozin | Small molecule | 10 mg | — |